KORU (KRMD) Q2 FY26 earnings call

KORU Medical Systems delivered a strong second quarter, marked by record revenue and a return to positive net income, driven by robust domestic and international core business growth. The company made a strategic acquisition of connected monitoring technology to enhance its drug delivery platform. While full-year revenue guidance was narrowed due to slower international market ramp-up, management remains confident in long-term opportunities and strategic pillars.